Advances in immunotherapy for colorectal malignancies
In the past decade, numerous advances have been made in resection, adjuvant treatment, and targeted therapies for colorectal malignancies; however, survival in the setting of metastatic disease treated with the most recent guideline-based therapy is only about 13 months. There has been mounting evidence that immune pathways are important in the development, progression, and regression of colorectal malignancies. This article explores the past attempts to harness immunotherapy against colorectal cancer and considers the future of colorectal cancer immunotherapeutics. Copyright © 2008 by Current Medicine Group LLC.
Volume / Issue
Start / End Page
Electronic International Standard Serial Number (EISSN)
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)